M. A. Kasper

Dr. Marc-André Kasper

Vice President, Chemistry and Early Discovery, Tubulis GmbH, IZB, Planegg-Martinsried, Germany

Lecture Title: Unsaturated Phosphonamidate Electrophiles as Versatile Reagents for the Construction of Next Generation Cancer Therapeutics

Thursday, 11 January 2024, 5.40 pm – 6.30 pm (MEZ)


Antibody-Drug-Conjugates (ADCs) hold great promise in cancer therapeutics by delivering a cytotoxic payload (drug) directly to the tumor, while sparing healthy tissue. Approved ADCs fall short in expectation. Linkers between drugs and antibodies are unstable in circulation, leading to severe side effects and reduced efficacy. At Tubulis, we are exploiting the unique properties of phosphonamidates as novel linker systems for ADCs, to generate superior ADCs in terms of stability in circulation, in vivo efficacy and PK.